What 503A Compounding Means for Your GLP-1 Medication

If you’ve been prescribed a compounded GLP-1 medication like semaglutide or tirzepatide, you may have seen the term “503A compounding pharmacy” and wondered what it actually means. Here’s the honest version, in plain language: what patient-specific compounding is, how a state-licensed 503A pharmacy operates, how to verify a pharmacy is legitimate, and how Boca sources its compounded medications through the WellSync network.

What a 503A Compounding Pharmacy Is

Boxed Warning — Thyroid C-Cell Tumors. Ozempic’s label and Zepbound’s label describe thyroid C-cell tumors in rodents; whether these drugs cause these tumors in humans is unknown. Both products are contraindicated — must not be used — in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). These are product-label warnings, not evidence that a compounded preparation has the same safety profile. Tell your prescriber about your medical and family history; compounding does not remove ingredient-related risks. This is not a complete list of warnings or contraindications.

A 503A pharmacy is the traditional compounding pharmacy. The “503A” designation comes from section 503A of the federal Food, Drug, and Cosmetic Act, which establishes the legal framework for patient-specific compounding.

Section 503A also permits limited anticipatory compounding under specified conditions. It is not a separate FDA pharmacy license. See FDA’s comparison of compounding frameworks.

What defines a 503A compounding pharmacy:

• It has a patient-specific prescription basis, with limited anticipatory compounding permitted under applicable conditions.
• It is licensed and overseen primarily by the state board of pharmacy in the state where it operates. The state board can inspect, discipline, or revoke the pharmacy’s license.
• It is expected to follow United States Pharmacopeia (USP) standards for sterile and non-sterile preparation — including USP <797> for sterile compounding (such as injectable medications) and USP <795> for non-sterile preparations — covering quality, testing, and beyond-use dating.
• Ask about the preparation’s beyond-use date and storage instructions. The “503A” label alone does not establish either.
• Federal exemptions are conditional. Preparations meeting all 503A conditions are exempt from federal current good manufacturing practice requirements; other applicable requirements remain. FDA retains oversight authority.

Patient-specific prescribing is one condition of the 503A framework. It does not by itself establish product quality or compliance with every compounding requirement.

How Patient-Specific Compounding Works

“Compounding” means a pharmacy prepares a medication rather than dispensing it pre-packaged from a drug manufacturer. A 503A pharmacy must meet the patient-specific prescription conditions, including limits on preparing medication before a prescription is received.

Section 503A restricts regular compounding, or compounding in inordinate amounts, of drugs that are essentially copies of commercially available products. FDA’s April 1, 2026 explanation addresses a prescriber’s documented determination that a change produces a significant difference for an identified patient. That determination does not waive other requirements.

That determination must be a genuine clinical judgment made for one individual. It is not a mechanism for providing a lower-cost version of a brand-name drug. The prescriber and pharmacist must assess the proposed preparation against all applicable conditions, not merely label it personalized.

Ask the prescriber what change is needed for you and ask the pharmacist how the preparation meets the applicable requirements. Do not select a dose or formulation yourself.

How 503B Outsourcing Facilities Differ

Section 503B is a separate framework for registered outsourcing facilities. Unlike qualifying 503A preparations, their drugs are subject to current good manufacturing practice requirements. FDA inspects these facilities on a risk-based schedule. See FDA’s outsourcing-facility explanation.

Outsourcing facilities may compound without obtaining patient-specific prescriptions, subject to other conditions. This does not authorize prescription-free retail dispensing. A 503B registration does not confer drug approval or remove ingredient and copying restrictions. The FDA comparison sets out the different conditions.

What “Not FDA-Approved” Means — and Why It Matters

This is the most misunderstood point in this category, so it is worth being direct.

Compounded semaglutide and tirzepatide are not FDA-approved drugs. The FDA does not approve the individual preparations made by compounding pharmacies. In the FDA’s own words: “Compounded drugs are not FDA-approved.”

FDA-approved drugs go through a rigorous premarket review process for safety, effectiveness, and manufacturing quality. Compounded drugs qualify for legal exemptions from certain requirements — not approval.

Compounded GLP-1 medications are not FDA-approved generics of Ozempic, Wegovy, Mounjaro, or Zepbound. A shared ingredient name does not establish equivalent clinical performance. Individual results vary and are not guaranteed. A state board license and a pharmacy’s quality testing reflect oversight of the pharmacy and its processes — not FDA approval of the medication itself.

If you encounter marketing language suggesting that a compounded GLP-1 is FDA-approved or equivalent to a brand-name product, treat that as a red flag.

How to Verify a 503A Pharmacy’s Legitimacy

Not all compounding pharmacies operate to the same standard. Here is what to look for and ask:

1. State board of pharmacy license. Every legitimate 503A pharmacy holds a current license from the state board of pharmacy in the state where it operates. Most state boards maintain a public license lookup tool. Find your state board of pharmacy through NABP. Confirm that the pharmacy dispensing your prescription is licensed and in good standing.

2. PCAB accreditation. The Accreditation Commission for Health Care (ACHC) offers PCAB (Pharmacy Compounding Accreditation Board) accreditation for compounding pharmacies that meet rigorous quality and safety standards. Accreditation is not required, but it is a meaningful signal of a pharmacy that has invited independent review of its practices.

3. USP standards compliance. Ask whether the pharmacy follows USP <797> for sterile compounding and USP <795> for non-sterile preparations. Reputable pharmacies can speak to their sterile practices, cleanroom standards, and quality assurance procedures.

4. Certificate of analysis (COA). Ask what material was tested, which lot it covers, and what methods, limits and actual results are reported. A COA may concern an ingredient rather than the finished medication; it does not necessarily cover every quality attribute or report passing results. FDA’s API guidance, section 11.4, describes ingredient certificates. Have the pharmacist explain which documentation covers your preparation.

5. Active pharmaceutical ingredient (API) sourcing. Ask who manufactured the ingredient and how its lot is traced. FDA’s statutory comparison describes registered-manufacturer, valid-COA and substance-eligibility conditions. A supplier’s registration claim alone does not prove that a particular ingredient or finished preparation meets all requirements.

6. Transparent answers from your provider. Ask directly: Which pharmacy fills my prescription? Is it currently licensed by its state board? Can I see a COA? A trustworthy provider answers these questions plainly. Vague or deflective responses are a signal worth taking seriously.

How Boca Sources Its Compounded GLP-1 Medications

Boca’s compounded GLP-1 medications are prescribed by licensed clinicians and filled by WellSync and other state-licensed 503A compounding pharmacies in the WellSync network, pursuant to a valid patient-specific prescription.

We qualify pharmacies in our network based on state licensing status, adherence to USP sterile compounding standards, third-party testing practices, and API sourcing. We are glad to tell you which pharmacy fills your prescription and to share information about how that pharmacy is tested and vetted.

We are not going to tell you that a state license or quality testing is the same as FDA approval — it is not, and you deserve the accurate version. What we will tell you: who makes your medication, how we qualify the pharmacies we work with, and whether compounded care is the right choice for you in the first place. If it is not, we will say so. That is the value of having a real clinician in the loop.

See how Boca sources and tests compounded medications →

The Compounding Landscape as of 2026

The regulatory context for compounded GLP-1 medications has shifted, and some information online has not caught up.

For a period, compounded GLP-1s were widely available because semaglutide and tirzepatide appeared on the FDA’s drug shortage list, which created a broad legal pathway for compounding. That window has narrowed. The FDA determined the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. In April 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The April 30 announcement invited comments before a final determination; it does not itself establish a permanent exclusion or a later final action.

A documented clinical rationale is not a blanket authorization. The prescription, ingredient, copying and other applicable conditions must also be met.

These dated announcements do not establish live shortage status or the legality of a particular prescription today. Ask the prescribing and dispensing professionals to check the current requirements.

Frequently Asked Questions

What is a 503A compounding pharmacy?

A 503A compounding pharmacy is a state-licensed pharmacy that prepares medications for individual patients based on a valid, patient-specific prescription. The designation comes from section 503A of the federal Food, Drug, and Cosmetic Act. These pharmacies are overseen primarily by state boards of pharmacy and are expected to follow USP standards for sterile and non-sterile compounding.

Is a compounded GLP-1 medication FDA-approved?

No. Compounded drugs — including compounded semaglutide and tirzepatide — are not FDA-approved. The FDA does not approve the individual preparations made by compounding pharmacies. Compounded GLP-1 medications are also not equivalent to and not interchangeable with FDA-approved brand-name products such as Ozempic, Wegovy, Mounjaro, or Zepbound. They are prepared for a specific patient under a licensed clinician’s direction, and individual results vary.

How do I know if a compounding pharmacy is legitimate?

Look for: a current state board of pharmacy license (verify through the state board’s public license lookup); PCAB accreditation through ACHC if available; confirmation that the pharmacy follows USP sterile compounding standards; testing documentation whose material, lot, methods and results the pharmacist can explain; and transparency about API sourcing. A trustworthy provider will answer these questions directly.

What does “significant difference” mean for a compounded GLP-1 prescription?

Under 503A, a clinician may determine that a compounded preparation produces a significant difference compared to the commercially available product for a specific patient — and document that clinical rationale. This is a genuine clinical judgment made for an individual. It is not a general workaround for cost or preference. The prescribing clinician must make and document this determination; it is not something a patient selects.

Where does Boca get its compounded GLP-1 medications?

Boca’s compounded GLP-1 medications are filled by WellSync and other state-licensed 503A compounding pharmacies in the WellSync network, pursuant to a valid patient-specific prescription written by a licensed clinician. Pharmacies in the network are vetted on state licensing, USP standards compliance, third-party testing practices, and API sourcing.

Can I choose my dose of compounded semaglutide?

No. Dosing for compounded GLP-1 medications is determined by your clinician based on your individual clinical needs and history. Clinician-directed dosing is a fundamental requirement of safe, legal, patient-specific compounded care.

Can compounding pharmacies still make semaglutide and tirzepatide now that the shortages are over?

The FDA determined the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. The April 30, 2026 announcement proposed excluding these substances from the 503B bulks list and invited comments; that announcement was not a final determination. A significant-difference determination addresses part of the 503A framework; all other applicable conditions must also be met. Historical shortage announcements do not determine whether a particular preparation is permissible today.

Related Articles

• Compounded Semaglutide Safety: What to Know
• Is Compounded Semaglutide FDA-Approved?
• Complete Guide to Semaglutide
• Microdosing Semaglutide: What to Know

Medical Disclaimer: This article is for educational purposes only and does not constitute medical or legal advice. Compounded medications are not FDA-approved and should only be used under the supervision of a licensed healthcare provider. Individual safety and effectiveness may vary, and reports of patient experience are anecdotal. Always verify the quality and source of any compounded medication, and discuss FDA-approved options with your clinician before starting treatment.

Regulatory Disclaimer: Compounded semaglutide and tirzepatide are not FDA-approved. The FDA does not review or verify the safety, quality, or effectiveness of compounded drugs. Compounding does not confer FDA-approved generic status or FDA-reviewed therapeutic equivalence. Lack of approval does not establish that no testing has ever occurred. A pharmacy’s state license or a facility’s registration is not the same as FDA approval of the medication. Information about FDA regulations is current as of publication date and subject to change.